Presentations at 26th EORTC-NCI-AACR Symposium Highlight Champions Oncology TumorGrafts’ Ability to Evaluate Immune-Modulating Therapies and Guide Clinical Development Strategies

Hackensack, NJ – November 19, 2014 – Champions Oncology (CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the delivery of two presentations at the 26th EORTC-NCI-AACR Symposium, held Nov. 18-21 in Barcelona, Spain, discussing the creation of an innovative TumorGraft model (ImmunoGraft) specific to immune-modulating therapeutics and benefits of Champions’ TumorGrafts® in guiding clinical development strategy.

“There continues to be a need for improved models that enable researchers to better understand the clinical potential of therapeutics early in their development, ideally in the preclinical setting,” said Keren Paz, Ph.D., chief scientific officer of Champions Oncology. “The findings presented at EORTC-NCI-AACR continue to demonstrate the advantages of our TumorGraft platform and our ability to create personalized mouse models for the exciting new class of immuno-oncology therapeutics. We look forward to presenting future case studies with our ImmunoGrafts at additional conferences in the year ahead.”

In a first study, titled “A humanized mouse model for preclinical testing of molecules targeting immune checkpoints,” Champions combined its TumorGraft technology with mice engineered to have a human immune system, creating a more accurate and reliable model for evaluating immune-modulating therapeutics. The resulting model, known as ImmunoGraft, will potentially allow for further understanding of interactions between the tumor and immune system to identify the most active drugs and potentially new drug targets. This presentation was granted the prestige status of abstract in the spotlight in the EORTC-NCI-AACR meeting.

In a second presentation, titled “Screening of Champions Predictive TumorGraft Platform Guides the Clinical Development of the Selective Dual BRAF-EGFR Inhibitor CEP-32496” the company described a case study completed with Teva Pharmaceuticals surrounding the development of a dual BRAF-EGFR inhibitor, CEP-32496. TumorGrafts were used to compare the efficacy of CEP-32496, both as monotherapy and in combination, against three approved therapeutics. Results demonstrated the robust therapeutic effect of CEP-32496 compared to the other therapeutics in colorectal cancer and melanoma models, supporting further development in clinical studies.